2026 Could Be Huge: Mizuho Predicts Major Stock Surge for Tango Therapeutics on Phase 1 Data

Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.